Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | CIPLA Cipla Limited Pharma · Large | IPCALAB IPCA Laboratories Limited Pharma · Large | AJANTPHARM Ajanta Pharma Limited Pharma · Large | GLAXO GlaxoSmithKline Pharmaceuticals Limited Pharma · Large |
|---|---|---|---|---|
| Final Score | 44 | 43 | 54 | 60 |
| Verdict | WATCHLIST | WATCHLIST | FAIR VALUE | UNDERVALUED |
| Style | WATCHLIST | WATCHLIST | Premium Compounder | Premium Compounder |
| Piotroski | 8/9 | 8/9 | 8/9 | 8/9 |
| Valuation | 10/30 | 0/30 | 4/30 | 4/30 |
| Growth | 11/25 | 10/25 | 13/25 | 11/25 |
| Quality | 2/20 | 12/20 | 17/20 | 20/20 |
| Balance Sheet | 9/15 | 9/15 | 11/15 | 12/15 |
| Cash Flow | 7/10 | 8/10 | 4/10 | 7/10 |
| Price | ₹1,374 | ₹1,635 | ₹3,017.2 | ₹2,194.7 |
| P/E | 29.50 | 34.80 | 35.10 | 36.20 |
| P/B | 3.26 | 5.19 | 8.20 | 16.30 |
| ROE | 11.60% | 16.00% | 25.40% | 48.40% |
| ROCE | 15.50% | 17.30% | 32.30% | 65.10% |
| Debt / Equity | 0.02 | 0.10 | 0.06 | 0.02 |
| FCF Yield | 1.52% | 2.14% | 0.27% | 3.51% |
| Dividend Y | 0.94% | 0.24% | 0.94% | 2.61% |
| Altman Z | 8.55 | 8.21 | 8.92 | 8.62 |
| Promoter % | 29.22% | 44.72% | 66.25% | 75.00% |
| Mkt Cap (₹Cr) | 112169.00 | 41817.00 | 37091.00 | 36995.00 |
| Graham # | ₹678.43 | ₹567.3 | ₹829.71 | ₹429.38 |
| Fair PE | 42.3 | 8.7 | 42.3 | 42.0 |
| MoS % | +32.4% | -317.3% | +15.6% | +14.6% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startCIPLA86
IPCALAB105
AJANTPHARM105
GLAXO86